• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

艰难梭菌感染。

Clostridium difficile Infection.

机构信息

Department of Medicine, Division of Infectious Disease and International Health, University of Virginia, Charlottesville, VA 22908.

Centro de Investigación en Enfermedades Tropicales, Facultad de Microbiología, Universidad de Costa Rica, Costa Rica.

出版信息

Microbiol Spectr. 2016 Jun;4(3). doi: 10.1128/microbiolspec.EI10-0007-2015.

DOI:10.1128/microbiolspec.EI10-0007-2015
PMID:27337475
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8118380/
Abstract

Clostridium difficile is an anaerobic, Gram-positive, spore-forming, toxin-secreting bacillus that has long been recognized to be the most common etiologic pathogen of antibiotic-associated diarrhea. C. difficile infection (CDI) is now the most common cause of health care-associated infections in the United States and accounts for 12% of these infections (Magill SS et al., N Engl J Med370:1198-1208, 2014). Among emerging pathogens of public health importance in the United States, CDI has the highest population-based incidence, estimated at 147 per 100,000 (Lessa FC et al., N Engl J Med372:825-834, 2015). In a report on antimicrobial resistance, C. difficile has been categorized by the Centers for Disease Control and Prevention as one of three "urgent" threats (http://www.cdc.gov/drugresistance/threat-report-2013/). Although C. difficile was first described in the late 1970s, the past decade has seen the emergence of hypertoxigenic strains that have caused increased morbidity and mortality worldwide. Pathogenic strains, host susceptibility, and other regional factors vary and may influence the clinical manifestation and approach to intervention. In this article, we describe the global epidemiology of CDI featuring the different strains in circulation outside of North America and Europe where strain NAP1/027/BI/III had originally gained prominence. The elderly population in health care settings has been disproportionately affected, but emergence of CDI in children and healthy young adults in community settings has, likewise, been reported. New approaches in management, including fecal microbiota transplantation, are discussed.

摘要

艰难梭菌是一种厌氧、革兰阳性、产芽孢、分泌毒素的杆菌,长期以来一直被认为是抗生素相关性腹泻最常见的病因病原体。艰难梭菌感染(CDI)现在是美国医疗保健相关感染的最常见原因,占这些感染的 12%(Magill SS 等人,N Engl J Med370:1198-1208, 2014)。在 美国具有公共卫生重要性的新兴病原体中,CDI 的发病率最高,估计为每 100,000 人中有 147 人(Lessa FC 等人,N Engl J Med372:825-834, 2015)。在一份关于抗菌药物耐药性的报告中,艰难梭菌被疾病预防控制中心列为三种“紧急”威胁之一(http://www.cdc.gov/drugresistance/threat-report-2013/)。尽管艰难梭菌于 20 世纪 70 年代末首次被描述,但在过去十年中,出现了产超毒素的菌株,导致全球发病率和死亡率上升。致病菌株、宿主易感性和其他地区因素各不相同,可能会影响临床表现和干预方法。在本文中,我们描述了 CDI 的全球流行病学特征,重点介绍了北美和欧洲以外地区流行的不同菌株。医疗机构中的老年人群受到了不成比例的影响,但在社区环境中,儿童和健康的年轻成年人中也出现了 CDI。还讨论了包括粪便微生物群移植在内的新管理方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b4f/8118380/1d8d64d3187a/nihms-1666976-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b4f/8118380/1d8d64d3187a/nihms-1666976-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b4f/8118380/1d8d64d3187a/nihms-1666976-f0001.jpg

相似文献

1
Clostridium difficile Infection.艰难梭菌感染。
Microbiol Spectr. 2016 Jun;4(3). doi: 10.1128/microbiolspec.EI10-0007-2015.
2
Epidemiology and clinical characteristics of Clostridium difficile infection in a Korean tertiary hospital.韩国一家三级医院艰难梭菌感染的流行病学和临床特征。
J Korean Med Sci. 2011 Oct;26(10):1258-64. doi: 10.3346/jkms.2011.26.10.1258. Epub 2011 Oct 1.
3
Clostridium difficile infection in an Iranian hospital.伊朗一家医院的艰难梭菌感染
BMC Res Notes. 2012 Mar 21;5:159. doi: 10.1186/1756-0500-5-159.
4
Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections.确定艰难梭菌感染期间TcdA和TcdB在局部胃肠道疾病、全身器官损伤及宿主反应中的作用。
mBio. 2015 Jun 2;6(3):e00551. doi: 10.1128/mBio.00551-15.
5
Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure.经直肠滴注艰难梭菌毒素 A 可引发结肠炎症和组织损伤:艰难梭菌毒素暴露的新型且高效的小鼠模型的建立。
Infect Immun. 2012 Dec;80(12):4474-84. doi: 10.1128/IAI.00933-12. Epub 2012 Oct 8.
6
Enterotoxic Clostridia: Infections.肠毒素梭菌:感染。
Microbiol Spectr. 2019 May;7(3). doi: 10.1128/microbiolspec.GPP3-0015-2018.
7
Clostridium difficile and the disease it causes.艰难梭菌及其引发的疾病。
Methods Mol Biol. 2010;646:9-35. doi: 10.1007/978-1-60327-365-7_2.
8
The Importance of Therapeutically Targeting the Binary Toxin from .靶向. 二元毒素治疗的重要性
Int J Mol Sci. 2021 Mar 13;22(6):2926. doi: 10.3390/ijms22062926.
9
Fluoroquinolone and Macrolide Exposure Predict Clostridium difficile Infection with the Highly Fluoroquinolone- and Macrolide-Resistant Epidemic C. difficile Strain BI/NAP1/027.氟喹诺酮类和大环内酯类药物的暴露可预测艰难梭菌感染,其感染菌株为对氟喹诺酮类和大环内酯类高度耐药的流行菌株BI/NAP1/027。
Antimicrob Agents Chemother. 2015 Nov 2;60(1):418-23. doi: 10.1128/AAC.01820-15. Print 2016 Jan.
10
The microbial metabolite urolithin A reduces toxin expression and toxin-induced epithelial damage.微生物代谢产物尿石素A可降低毒素表达及毒素诱导的上皮损伤。
mSystems. 2024 Feb 20;9(2):e0125523. doi: 10.1128/msystems.01255-23. Epub 2024 Jan 9.

引用本文的文献

1
Lipidomics, Microbiota, and Intestinal Infection Outcome.脂质组学、微生物群与肠道感染结果
Int J Mol Sci. 2025 Aug 24;26(17):8214. doi: 10.3390/ijms26178214.
2
Novel insights into ORFV B2L DNA vaccine-mediated gut microbiota modulation and immune augmentation in rats.对羊口疮病毒B2L DNA疫苗介导的大鼠肠道微生物群调节和免疫增强的新见解。
Front Immunol. 2025 Jul 18;16:1598969. doi: 10.3389/fimmu.2025.1598969. eCollection 2025.
3
Clostridioides (Clostridium) difficile: A silent nosocomial pathogen.艰难梭菌(梭状芽孢杆菌):一种沉默的医院病原体。

本文引用的文献

1
The Long-term Efficacy and Safety of Fecal Microbiota Transplant for Recurrent, Severe, and Complicated Clostridium difficile Infection in 146 Elderly Individuals.146例老年复发性、重度及复杂性艰难梭菌感染患者粪便微生物群移植的长期疗效和安全性
J Clin Gastroenterol. 2016 May-Jun;50(5):403-7. doi: 10.1097/MCG.0000000000000410.
2
Racial Differences in Clostridium difficile Infection Rates Are Attributable to Disparities in Health Care Access.艰难梭菌感染率的种族差异归因于医疗保健可及性的差异。
Antimicrob Agents Chemother. 2015 Oct;59(10):6283-7. doi: 10.1128/AAC.00795-15. Epub 2015 Jul 27.
3
Prevalence of gastrointestinal pathogenic bacteria in patients with diarrhoea attending Groote Schuur Hospital, Cape Town, South Africa.
Saudi Med J. 2023 Sep;44(9):825-835. doi: 10.15537/smj.2023.44.9.20230216.
4
Outcomes of Continuous Enteral Vancomycin Infusion in Intensive Care Unit Patients: A Novel Treatment Modality for Severe Clostridium Difficile Colitis.重症监护病房患者持续肠内输注万古霉素的治疗效果:一种针对严重艰难梭菌结肠炎的新型治疗方式
Cureus. 2022 Mar 5;14(3):e22872. doi: 10.7759/cureus.22872. eCollection 2022 Mar.
5
Bacteriophage endolysins as a potential weapon to combat infection.噬菌体溶菌素作为对抗感染的潜在武器。
Gut Microbes. 2020 Nov 9;12(1):1813533. doi: 10.1080/19490976.2020.1813533.
6
Imaging Inflammation and Infection in the Gastrointestinal Tract.胃肠道炎症和感染的影像学诊断
Int J Mol Sci. 2019 Dec 30;21(1):243. doi: 10.3390/ijms21010243.
7
Vegetative Cell and Spore Proteomes of Show Finite Differences and Reveal Potential Protein Markers.示芽胞杆菌的营养细胞和芽胞的蛋白质组具有明显的差异,这揭示了潜在的蛋白质标志物。
J Proteome Res. 2019 Nov 1;18(11):3967-3976. doi: 10.1021/acs.jproteome.9b00413. Epub 2019 Oct 14.
8
A Novel Bacteriophage Lysin-Human Defensin Fusion Protein Is Effective in Treatment of Infection in Mice.一种新型噬菌体裂解素-人类防御素融合蛋白对小鼠感染治疗有效。
Front Microbiol. 2019 Jan 11;9:3234. doi: 10.3389/fmicb.2018.03234. eCollection 2018.
9
Fecal microbiota transplantation: donor relation, fresh or frozen, delivery methods, cost-effectiveness.粪便微生物群移植:供体关系、新鲜或冷冻、递送方法、成本效益。
Ann Gastroenterol. 2019 Jan-Feb;32(1):30-38. doi: 10.20524/aog.2018.0328. Epub 2018 Nov 17.
10
Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection.接受 bezlotoxumab 联合抗菌药物治疗艰难梭菌感染的住院患者的 30 天再入院率。
Clin Infect Dis. 2017 Oct 1;65(7):1218-1221. doi: 10.1093/cid/cix523.
南非开普敦古特·舒尔医院腹泻患者胃肠道病原菌的患病率
S Afr Med J. 2015 Jan 5;105(2):121-5. doi: 10.7196/samj.8654.
4
Surveillance for antimicrobial resistance in Australian isolates of Clostridium difficile, 2013-14.2013 - 2014年澳大利亚艰难梭菌分离株的抗菌药物耐药性监测
J Antimicrob Chemother. 2015 Nov;70(11):2992-9. doi: 10.1093/jac/dkv220. Epub 2015 Jul 28.
5
The Addition of Intravenous Metronidazole to Oral Vancomycin is Associated With Improved Mortality in Critically Ill Patients With Clostridium difficile Infection.静脉注射甲硝唑联合口服万古霉素可改善艰难梭菌感染的危重症患者的死亡率。
Clin Infect Dis. 2015 Sep 15;61(6):934-41. doi: 10.1093/cid/civ409. Epub 2015 May 29.
6
Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial.非产毒艰难梭菌 M3 菌株孢子给药预防复发性艰难梭菌感染:一项随机临床试验。
JAMA. 2015 May 5;313(17):1719-27. doi: 10.1001/jama.2015.3725.
7
Differences of the Fecal Microflora With Clostridium difficile Therapies.艰难梭菌治疗的粪便微生物群差异。
Clin Infect Dis. 2015 May 15;60 Suppl 2:S91-7. doi: 10.1093/cid/civ252.
8
First report of Clostridium difficile NAP1/027 in a Mexican hospital.墨西哥一家医院艰难梭菌NAP1/027的首次报告。
PLoS One. 2015 Apr 27;10(4):e0122627. doi: 10.1371/journal.pone.0122627. eCollection 2015.
9
The first Clostridium difficile ribotype 027 strain isolated in Taiwan.台湾分离出的首例艰难梭菌核糖体分型027菌株。
J Formos Med Assoc. 2016 Mar;115(3):210-2. doi: 10.1016/j.jfma.2015.02.006. Epub 2015 Mar 17.
10
Emergence and spread of predominantly community-onset Clostridium difficile PCR ribotype 244 infection in Australia, 2010 to 2012.2010 年至 2012 年澳大利亚主要社区获得性艰难梭菌 PCR 核糖型 244 感染的出现和传播。
Euro Surveill. 2015 Mar 12;20(10):21059. doi: 10.2807/1560-7917.es2015.20.10.21059.